A Phase 3 interventional study of Enoxaparin and warfarin in Venous Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 382 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-21.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing apixaban in Venous Thrombosis — 5 open to participants now, 6 under way, 1 of them phase 3. apixaban · Venous Thrombosis.
Among the 26 studies testing apixaban in Venous Thrombosis, this one is the 2nd largest by enrollment, is one of 2 that started in 2008, is one of 10 in phase 3, and was the 6th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →5 of the 26 studies testing apixaban in Venous Thrombosis are open now, in 3 countries. Recruiting first, the newest first:
Rushad Patell · Sites in United States
Ages 18+
Clinical Urology and Epidemiology Working Group · Sites in Finland
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
James Bayley · Sites in United States
Ages 18+
University Hospital, Geneva
Ages 18–120
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 12 · Phase 4 10
First in 2004; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,614 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 445 across the 26 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 26 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 9 studies filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
3 of the studies testing apixaban in Venous Thrombosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
| NCT07713875James BayleyExtended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies testing apixaban in Venous Thrombosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
Drug: Enoxaparin · Drug: warfarin · Drug: Placebo for apixaban
Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.
Drug: Placebo for enoxaparin · Drug: Placebo for warfarin · Drug: apixaban
solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.
tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Also known as: Coumadin, BMS-565793
tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Also known as: BMS-562247
Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment
VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat).
Time frame: Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)
Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded.
Time frame: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite.
Time frame: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle
Time frame: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding
VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT).
Time frame: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period
DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).
Time frame: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period
PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).
Time frame: Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)
Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Incidence of All-Cause Death During the Intended Treatment Period
Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information).
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants
All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants
Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug).
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants
Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants
Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants
Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants
Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued
Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: \< 0.75\*LLN, \> 1.25\*ULN; Hemoglobin: \<= 11.5 g/dL (males), \<= 9.5 g/dL (females); Hematocrit: \<= 37% (males), \<= 32% (females); Erythrocytes: \<0.75\*10\^6 c/µL\*PreRx; Platelet count: \< 75\*10\^9 c/L, \> 700\*10\^9 c/L; ANC: \< 1.00\*10\^3 c/µL; Abs eosinophils: \> 0.750\*10\^3 c/µL; Abs Basophils: \> 400/MM\^3; Abs Monocytes\> 2000/MM\^3; Abs Lymphocytes: \< 0.750\*10\*3 c/ µL, \> 7.5\*10\^3 c/ µL.
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: \< 0.75\*LLN or \> 1.25\*ULN, or if pre-dose \< LLN then use \< 0.75\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.25\*pre-dose or \< LLN; Serum Calcium mg/dL Low/High: \< 0.8\*LLN or \> 1.2\*ULN, or if pre-dose \< LLN then use \< 0.75\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.25\*pre-dose or \< LLN; Serum Chloride mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use \< 0.9\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.1\*pre-dose or \< LLN; Serum Potassium mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use \< 0.9\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.1\*pre-dose or \< LLN; Serum Sodium mEq/L: \< 0.95\*LLN or \> 1.05\*ULN, or if pre-dose \< LLN then use \< 0.95\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.05\*pre-dose or \< LLN.
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: \> 1.5\*ULN; Creatinine mg/dL: \> 1.5\*ULN; Alanine aminotransferase (ALT) U/L: \> 3\*ULN; Aspartate aminotransferase (AST) U/L: \> 3\*ULN; Alkaline phosphatase U/L: \> 2\*ULN; Bilirubin Direct mg/dL: \> 1.5\*ULN; Bilirubin Total mg/dL: \> 2\*ULN.
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Number of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests
Creatine kinase High: \>5\*ULN Units/Liter (U/L); Total Protein High/Low: \< 0.9 \*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use 0.9\* pre-dose or \> ULN if pre-dose \> ULN then use 1.1 \*pre-dose or \<LLN; Uric acid High: \> 1.5\* ULN, or if pre-dose \> ULN then use \> 2 \*pre-dose.
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests
All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4.
Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
First participant, first visit: 27 August 2008; Last participant, last visit: 12 March 2013.
| Milestone | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Started | 2691 | 2704 |
| Completed | 2314 | 2291 |
| Not completed | 377 | 413 |
| Withdrew: Death | 20 | 26 |
| Withdrew: Adverse event | 150 | 182 |
| Withdrew: Withdrawal by subject | 49 | 49 |
| Withdrew: Lost to follow-up | 14 | 14 |
| Withdrew: Poor or non-compliance | 20 | 23 |
| Withdrew: Pregnancy | 3 | 2 |
| Withdrew: Fails to meet inclusion/exclusion | 13 | 9 |
| Withdrew: Administrative reason | 1 | 1 |
| Withdrew: Other | 107 | 107 |
| Milestone | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Started | 2617 | 2639 |
| Completed | 2547 | 2560 |
| Not completed | 70 | 79 |
| Withdrew: Death | 28 | 34 |
| Withdrew: Withdrawal by subject | 23 | 29 |
| Withdrew: Lost to follow-up | 18 | 16 |
| Withdrew: Non-specified | 1 | 0 |
VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat).
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment | 0.0226 (0.0169 to 0.0283) | 0.0269 (0.0208 to 0.0331) |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded.
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death | 0.0322 (0.0254 to 0.0390) | 0.0395 (0.0320 to 0.0469) |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite.
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death | 0.0234 (0.0176 to 0.0292) | 0.0292 (0.0228 to 0.0357) |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding | 0.0280 (0.0216 to 0.0343) | 0.0448 (0.0369 to 0.0527) |
VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT).
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding | 0.0699 (0.0602 to 0.0797) | 0.1261 (0.1134 to 0.1387) |
DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period | 0.0084 (0.0049 to 0.0119) | 0.0133 (0.0089 to 0.0177) |
PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period | 0.0104 (0.0065 to 0.0142) | 0.0095 (0.0058 to 0.0132) |
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period | 0.0046 (0.0020 to 0.0072) | 0.0061 (0.0031 to 0.0091) |
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period | 0.0058 (0.0028 to 0.0087) | 0.0087 (0.0052 to 0.0123) |
Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information).
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of All-Cause Death During the Intended Treatment Period | 0.0157 (0.0109 to 0.0205) | 0.0198 (0.0145 to 0.0251) |
All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants | 0.0056 (0.0028 to 0.0084) | 0.0182 (0.0132 to 0.0233) |
Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug).
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants | 0.0430 (0.0353 to 0.0507) | 0.0971 (0.0859 to 0.1083) |
Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants | 0.0385 (0.0312 to 0.0458) | 0.0800 (0.0697 to 0.0902) |
Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants | 0.1170 (0.1048 to 0.1291) | 0.1878 (0.1730 to 0.2026) |
Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.
| proportion of participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants | 0.1502 (0.1367 to 0.1638) | 0.2514 (0.2350 to 0.2678) |
Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| AE | 1795 | 1923 |
| SAE | 417 | 410 |
| Bleeding AE or SAE | 415 | 695 |
| Discontinued Due to AE or SAE | 162 | 199 |
| Death | 37 | 44 |
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: \< 0.75\*LLN, \> 1.25\*ULN; Hemoglobin: \<= 11.5 g/dL (males), \<= 9.5 g/dL (females); Hematocrit: \<= 37% (males), \<= 32% (females); Erythrocytes: \<0.75\*10\^6 c/µL\*PreRx; Platelet count: \< 75\*10\^9 c/L, \> 700\*10\^9 c/L; ANC: \< 1.00\*10\^3 c/µL; Abs eosinophils: \> 0.750\*10\^3 c/µL; Abs Basophils: \> 400/MM\^3; Abs Monocytes\> 2000/MM\^3; Abs Lymphocytes: \< 0.750\*10\*3 c/ µL, \> 7.5\*10\^3 c/ µL.
| participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Erthrocytes Low (N=2599, 2593) | 23 | 17 |
| Hematocrit Low (N=2588, 2587) | 26 | 20 |
| Hemoglobin Low (N=2599, 2593) | 96 | 101 |
| Platelet Count Low (N=2594, 2589) | 23 | 13 |
| Leukocytes Low (N=2528, 2519) | 41 | 41 |
| Leukocytes High (N=2528, 2519) | 26 | 15 |
| Absolute Basophils High (N=2594,2589) | 1 | 2 |
| Absolute Eosinophils High (N=2594,2589) | 84 | 79 |
| Absolute Lyphocytes Low (N=2594,2589) | 94 | 76 |
| Absolute Lyphocytes High (N=2594,2589) | 4 | 3 |
| Absolute Monocytes High (N=2594,2589) | 1 | 2 |
| Absolute Neutrophils Low (N=2594,2589) | 9 | 20 |
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: \< 0.75\*LLN or \> 1.25\*ULN, or if pre-dose \< LLN then use \< 0.75\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.25\*pre-dose or \< LLN; Serum Calcium mg/dL Low/High: \< 0.8\*LLN or \> 1.2\*ULN, or if pre-dose \< LLN then use \< 0.75\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.25\*pre-dose or \< LLN; Serum Chloride mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use \< 0.9\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.1\*pre-dose or \< LLN; Serum Potassium mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use \< 0.9\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.1\*pre-dose or \< LLN; Serum Sodium mEq/L: \< 0.95\*LLN or \> 1.05\*ULN, or if pre-dose \< LLN then use \< 0.95\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.05\*pre-dose or \< LLN.
| participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Bicarbonate Low (N=2600,2593) | 44 | 31 |
| Bicarbonate High (N=2600,2593) | 17 | 11 |
| Total Calcium Low (N=2601,2596) | 3 | 10 |
| Total Calcium High (N=2601,2596) | 12 | 11 |
| Chloride Low Total Calcium Low (N=2601,2596) | 5 | 3 |
| Chloride Low Total Calcium High (N=2601,2596) | 0 | 1 |
| Potassium Low (N=2601,2596) | 26 | 22 |
| Potassium High (N=2601,2596) | 19 | 22 |
| Sodium Low (N=2601,2596) | 10 | 6 |
| Sodium Low (N=2601,2596) | 4 | 4 |
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: \> 1.5\*ULN; Creatinine mg/dL: \> 1.5\*ULN; Alanine aminotransferase (ALT) U/L: \> 3\*ULN; Aspartate aminotransferase (AST) U/L: \> 3\*ULN; Alkaline phosphatase U/L: \> 2\*ULN; Bilirubin Direct mg/dL: \> 1.5\*ULN; Bilirubin Total mg/dL: \> 2\*ULN.
| participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| BUN High (N=517, 523) | 2 | 7 |
| Creatinine High (N=2601, 2596) | 47 | 37 |
| ALT High (N=2601, 2598) | 52 | 145 |
| ALP High (N=2601, 2598) | 35 | 27 |
| AST High (N=2601, 2598) | 40 | 40 |
| Direct Bilirubin High (N=2601, 2593) | 28 | 21 |
| Total Bilirubin High (N=2601, 2597) | 8 | 7 |
Creatine kinase High: \>5\*ULN Units/Liter (U/L); Total Protein High/Low: \< 0.9 \*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use 0.9\* pre-dose or \> ULN if pre-dose \> ULN then use 1.1 \*pre-dose or \<LLN; Uric acid High: \> 1.5\* ULN, or if pre-dose \> ULN then use \> 2 \*pre-dose.
| participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Creatine Kinase High (N=2601, 2596) | 20 | 24 |
| Uric Acid High (N=2601, 2596) | 6 | 3 |
| Total Protein Low (N=2601, 2596) | 15 | 16 |
| Total Protein High (N=2601, 2596) | 0 | 0 |
All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4.
| participants | Apixaban | Enoxaparin + Warfarin |
|---|---|---|
| Blood in Urine High (N=2289, 2273) | 85 | 127 |
| Glucose in Urine High (N=2289, 2273) | 46 | 31 |
| Leukocyte Esterase in Urine High (N=2289, 2273) | 105 | 102 |
| Protein in Urine High (N=2289, 2273) | 41 | 50 |
| RBC + WBC in Urine High (N=1685, 1719) | 359 | 361 |
| RBC in Urine High (N=1293, 1389) | 111 | 140 |
| WBC in Urine High (N=1354, 1361) | 274 | 263 |
Collected over Day 1 up to 24 Weeks + 2 Days or 355 Days (for those participants who discontinued early)/. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apixaban | — | 417/2,676 (15.6%) | 1,014/2,676 (37.9%) |
| Enoxaparin/Warfarin | — | 410/2,689 (15.2%) | 1,207/2,689 (44.9%) |
| Event | Apixaban | Enoxaparin/Warfarin |
|---|---|---|
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 24/2676 | 38/2689 |
| DEEP VEIN THROMBOSISVascular disorders | 20/2676 | 33/2689 |
| PNEUMONIAInfections and infestations | 16/2676 | 12/2689 |
| OVERDOSEInjury, poisoning and procedural complications | 15/2676 | 11/2689 |
| GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 8/2676 | 14/2689 |
| HAEMATURIARenal and urinary disorders | 5/2676 | 13/2689 |
| NON-CARDIAC CHEST PAINGeneral disorders | 9/2676 | 6/2689 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 9/2676 | 6/2689 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 9/2676 | 5/2689 |
| URINARY TRACT INFECTIONInfections and infestations | 8/2676 | 3/2689 |
| Event | Apixaban | Enoxaparin/Warfarin |
|---|---|---|
| HEADACHENervous system disorders | 169/2676 | 167/2689 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 77/2676 | 144/2689 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 119/2676 | 130/2689 |
| OEDEMA PERIPHERALGeneral disorders | 93/2676 | 111/2689 |
| DIARRHOEAGastrointestinal disorders | 100/2676 | 106/2689 |
| NAUSEAGastrointestinal disorders | 81/2676 | 106/2689 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 30/2676 | 105/2689 |
| NASOPHARYNGITISInfections and infestations | 104/2676 | 98/2689 |
| CONTUSIONInjury, poisoning and procedural complications | 48/2676 | 97/2689 |
| URINARY TRACT INFECTIONInfections and infestations | 92/2676 | 82/2689 |
Randomized Participants
| Age, Continuous(years) | Apixaban | Enoxaparin + Warfarin | Total |
|---|---|---|---|
| Mean | 57.2 ± 15.98 | 56.7 ± 16.01 | 56.9 ± 16.00 |
| Age, Customized(participants) | Apixaban | Enoxaparin + Warfarin | Total |
|---|---|---|---|
| Less than (<) 65 | 1729 | 1762 | 3491 |
| 65 to < 75 | 560 | 570 | 1130 |
| Greater than, equal to (>=) 75 | 402 | 372 | 774 |
| Sex: Female, Male(Participants) | Apixaban | Enoxaparin + Warfarin | Total |
|---|---|---|---|
| Female | 1122 | 1106 | 2228 |
| Male | 1569 | 1598 | 3167 |
| Race/Ethnicity, Customized(participants) | Apixaban | Enoxaparin + Warfarin | Total |
|---|---|---|---|
| White | 2218 | 2243 | 4461 |
| Black or African American | 106 | 98 | 204 |
| American Indian or Alaska Native | 6 | 2 | 8 |
| Asian | 227 | 226 | 453 |
| Other Race | 89 | 85 | 174 |
| Race Not Reported | 45 | 50 | 95 |
| Hispanic or Latino | 20 | 18 | 38 |
| Not Hispanic or Latino | 367 | 380 | 747 |
| Ethnicity Not Reported | 2304 | 2306 | 4610 |
| Region of Enrollment(participants) | Apixaban | Enoxaparin + Warfarin | Total |
|---|---|---|---|
| Portugal | 10 | 9 | 19 |
| United States | 387 | 398 | 785 |
| Hong Kong | 2 | 1 | 3 |
| Spain | 56 | 51 | 107 |
| Ukraine | 213 | 211 | 424 |
| Israel | 162 | 163 | 325 |
| Russian Federation | 178 | 174 | 352 |
| Italy | 167 | 169 | 336 |
| India | 101 | 99 | 200 |
| France | 140 | 149 | 289 |
| Malaysia | 0 | 2 | 2 |
| Australia | 56 | 64 | 120 |
| Denmark | 69 | 72 | 141 |
| South Africa | 70 | 77 | 147 |
| China | 113 | 114 | 227 |
| Korea, Republic of | 2 | 2 | 4 |
| Austria | 40 | 39 | 79 |
| Czech Republic | 140 | 134 | 274 |
| Hungary | 145 | 128 | 273 |
| Mexico | 59 | 57 | 116 |
| Canada | 147 | 152 | 299 |
| Argentina | 17 | 16 | 33 |
| Poland | 60 | 59 | 119 |
| Brazil | 77 | 81 | 158 |
| Singapore | 5 | 5 | 10 |
| Romania | 33 | 41 | 74 |
| Norway | 40 | 32 | 72 |
| Germany | 202 | 205 | 407 |
| Qualifying index Venous Thromboembolic Embolism(participants) | Apixaban | Enoxaparin + Warfarin | Total |
|---|---|---|---|
| Provoked Index VTE | 272 | 272 | 544 |
| Unprovoked Index VTE | 2416 | 2429 | 4845 |
| Not Reported | 3 | 3 | 6 |
| Index Event Classification(participants) | Apixaban | Enoxaparin + Warfarin | Total |
|---|---|---|---|
| Proximal DVT | 1778 | 1814 | 3592 |
| PE | 913 | 890 | 1803 |
| Adjudicated Proximal DVT | 1749 | 1783 | 3532 |
| Adjudicated PE | 930 | 906 | 1836 |
Showing the first 100 of 382 sites across 31 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2008, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban